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Abstract
Rotavirus is the leading cause of diarrheal death among children <5 years old worldwide, 
estimated to have caused ~215,000 deaths in 2013. Prior to rotavirus vaccine implementation, 
>65% of children had at least one rotavirus diarrhea illness by 5 years of age and rotavirus 
accounted for >40% of all-cause diarrhea hospitalizations globally. Two live, oral rotavirus 
vaccines have been implemented nationally in >100 countries since 2006 and their use has 
substantially reduced the burden of severe diarrheal illness in all settings. Vaccine efficacy and 
effectiveness estimates suggest there is a gradient in vaccine performance between low-child 
mortality countries (>90%) and medium- and high-child mortality countries (57–75%). 
Additionally, an increased risk of intussusception (~1–6 per 100,000 vaccinated infants) following 
vaccination has been documented in some countries, but this is outweighed by the large benefits of 
vaccination. Two additional live, oral rotavirus vaccines were recently licensed and these have 
improved on some programmatic limitations of earlier vaccines, such as heat stability, cost, and 
cold-chain footprint. Non-replicating rotavirus vaccines that are parenterally administered are in 
clinical testing, and these have the potential to reduce the performance differential and safety 
concerns associated with live oral rotavirus vaccines.
1. Introduction
Rotavirus is a significant cause of diarrheal hospitalizations and deaths among children <5 
years old worldwide [1, 2]. Symptoms of rotavirus infection include watery diarrhea, 
vomiting, and fever. Rotavirus is primarily spread through the fecal-oral route [3]. Since 
their licensure in 2006, rotavirus vaccines have dramatically reduced the disease burden. 
However, vaccines are not yet routinely available in all countries and there are limitations to 
the currently licensed vaccines. In this article, we present the current state of rotavirus 
disease burden and vaccines and discuss post-licensure rotavirus vaccine effectiveness, 
impact, and safety.
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Prior to the availability of rotavirus vaccines, rotavirus infection was a common experience 
for children <5 years old. Studies of the natural history of rotavirus infections during the 
pre-vaccine era in Australia, Bangladesh, Canada, Guinea Bissau, India, and Mexico found 
64–80% of children had at least one rotavirus infection in infancy and early childhood [4–9]. 
In 2013, an estimated 215 000 deaths due to rotavirus diarrhea among children <5 years of 
age occurred worldwide, of which >95% occurred in countries in Africa and Asia [2]. 
Estimated rotavirus mortality rates by country are visualized in Figure 1. Rotavirus 
infections also represent a significant proportion of diarrhea hospitalizations in young 
children [10]. The Global Rotavirus Surveillance Network, a sentinel hospital-based active 
surveillance system for diarrhea coordinated by the World Health Organization (WHO) has 
found that rotavirus accounted for over one third of diarrhea hospitalizations before the 
vaccine was introduced [11].
3. Rotavirus biology and immunity
Rotavirus consists of a non-enveloped RNA virus with a segmented genome surrounded by a 
triple-layered protein capsid [12, 13]. While many species of animals can be infected by 
rotavirus, human infections are primarily caused by group A; two structural proteins in the 
outer layer, VP7, the G protein, and VP4, the P protein, determine the genotype [12–14]. In 
a synthesis of 30 years of pre-vaccine data, more than two thirds of rotavirus infections 
globally were attributed to G1P[8] and an additional 20% were due to G2P[4], G3P[8], and 
G4P[8] [14]. There is some variation in circulating genotypes by year and region, for 
example G1P[8] accounted for just 23% of infections in Africa and 34% in Asia. More 
recently, G9 and G12 viruses have contributed to a larger proportion of global rotavirus 
infections [15].
Initial natural rotavirus infections, including asymptomatic neonatal infections, have been 
shown to reduce the frequency and severity of subsequent rotavirus infections during 
childhood and beyond [4, 5, 7, 16]. First natural infections were 56–77% efficacious against 
later rotavirus infections and increased with each subsequent; protection was higher against 
diarrheal illness caused by rotavirus [5, 7, 16]. Rotavirus infections also offer some 
protection against other strains of rotavirus causing diarrheal disease [4, 5]. These findings 
provided the rationale for the development of an infant vaccine against rotavirus. Despite 
this body of research, no good correlate of protection against diarrheal disease due to 
rotavirus has been identified.
4. Licensed rotavirus vaccines
Since 2006, two live, oral rotavirus vaccines have been licensed in >100 countries and pre-
qualified by the World Health Organization (WHO). RotaTeq (Merck and Co) is a three-
dose, pentavalent bovine-human reassortant rotavirus vaccine that is distributed in a single, 
2mL dose vial and Rotarix (GSK Biologics) is a two-dose, monovalent human G1P[8] 
rotavirus vaccine that is distributed in a single, 1.5mL dose vial (Table 1) [17–19]. As of 
September 2017, more than 80 countries have introduced rotavirus vaccine into their 
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national, routine infant vaccination programs (Figure 2) [20, 21]. Two newly-licensed live, 
oral rotavirus vaccines, Rotasiil (Serum Institute of India), a three-dose, pentavalent bovine-
human reassortant vaccine, and ROTAVAC (Bharat Biotech), a three-dose, monovalent 
human-bovine G9P[11] vaccine, are seeking WHO pre-qualification as of 2017 [22–24]. In 
addition to these four vaccines, domestically licensed live, oral rotavirus vaccines are 
available in China (LLR, Lanzhou Institute of Biological Produces) and Vietnam (Rotavin, 
PolyVac) [24].
Clinical trials of vaccine efficacy and post-licensure effectiveness evaluations of RotaTeq 
and Rotarix in high and upper-middle income countries demonstrated that the vaccines were 
>90% effective in preventing severe rotavirus disease [17, 18, 25–28]. However, clinical 
trials in countries with higher child mortality found that rotavirus vaccines were less 
efficacious in these settings, with published efficacy estimates ranging from 50–64% [29–
31]. Similar to the results from the clinical trials of RotaTeq and Rotarix, ROTAVAC’s 
vaccine efficacy against hospitalization for rotavirus diarrhea was 54% in a clinical trial in 
India and Rotasiil’s was 67% in a clinical trial in Niger and 39% in India [22, 23, 32].
ROTAVAC and Rotasiil promised improvements on certain programmatic aspects of Rotarix 
and RotaTeq. For example, ROTAVAC is expected to cost USD$1 and Rotasiil is expected to 
cost USD$2.50 per dose, compared to approximately USD$3.20 for RotaTeq and USD$2.50 
for Rotarix through UNICEF’s supply division [22, 23, 33, 34]. Additionally, ROTAVAC’s 
presentation as a 0.5mL vaccine in a 5-dose vial reduces the required space in the cold chain 
and associated costs [19, 24]. Rotasiil, a lyophilized vaccine, is heat stable for 6 months at 
40°C; the clinical trial for Rotasiil in Niger found the vaccine was efficacious after storage at 
up to 25°C in the distribution facility and at the ambient temperature once distributed to the 
vaccination centers [23, 35]. This demonstrated heat stability could reduce the burden on the 
cold chain, as well as the financial costs and forecasting challenges associated with vaccine 
wastage due to temperature excursions [36, 37].
5. Vaccine effectiveness
A recent systematic review of post-licensure vaccine effectiveness (VE) evaluations in 
countries using RotaTeq and Rotarix supported the clinical trial findings that suggested 
differential vaccine performance between low and high children mortality countries (as 
ROTAVAC and Rotasiil are recently licensed and not yet introduced on a national scale, they 
were not included in the literature review). Jonesteller et al reported median Rotarix VE of 
84% in low child mortality countries, 75% in medium child mortality countries, and 57% in 
high child mortality countries (Table 2) [38]. Comparably, median RotaTeq VE was 90% in 
low child mortality countries and 45% in high child mortality countries [38].
Because many of the post-licensure evaluations have not been sufficiently powered to detect 
differences between subpopulations, the systematic review also aimed to clarify questions of 
VE with a partially completed vaccination series and against a range of disease severities 
through summary statistics. For Rotarix in low child mortality countries, VE was nearly the 
same for children who received the full number of the manufacturer recommended doses and 
children who only were partially vaccinated; the median reported difference was 3 
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percentage points. In medium and high child mortality countries, VE was higher in children 
who received the full-series compared to children who received a single dose, with a median 
difference of 10 and 19 percentage points, respectively. For RotaTeq in low child mortality 
countries, VE was higher among fully vaccinated children compared to children who 
received only one or two doses, with a median difference of 16 percentage points. A single 
evaluation from a high child mortality country using RotaTeq showed that VE was 65 higher 
among fully vaccinated children compared with partially vaccinated children [38].
The review found articles defined severity in two ways: by hospitalization status (i.e. 
emergency department or inpatient) and by Vesikari score. Vesikari score is a grading of 
seven clinical signs and symptoms; higher numeric values on the 20-point scale indicate 
more severe and dehydrating diarrheal illness [39]. In low child mortality countries, the 
median difference in VE was slightly higher among hospitalized children compared to those 
treated in the emergency department for both vaccines, with a median difference of 5 
percentage points for Rotarix and 9 percentage points for RotaTeq [38]. While there is some 
variation, overall these results indicate higher effectiveness against more severe rotavirus 
disease in a variety of settings. In medium child mortality countries, Rotarix VE was a 
median 25% lower among children with high Vesikari scores compared to lower scores. In 
high child mortality countries, the median difference in VE was 17 and 16 percentage points 
higher among children with high Vesikari scores compared to those with low scores using 
Rotarix and RotaTeq, respectively [38].
6. Explaining and improving performance of oral rotavirus vaccines in 
developing countries
The exact reasons for the gradient in VE between low, medium, and high child mortality 
countries are unknown, however several factors are known to reduce the effectiveness of 
these vaccines. Other oral vaccines, such as cholera and polio, have also demonstrated lower 
effectiveness in low income settings. Co-infections with other enteric pathogens at the time 
of vaccination inhibits immune response to rotavirus vaccine, as well as oral polio vaccine 
[40, 41]. Transplacental maternal rotavirus antibodies have been shown to reduce vaccine-
induced immunity in young infants [42–44]. Some improvement to VE may occur naturally 
as the global polio program transitions from live oral polio vaccine to injectable 
formulations. Polio and rotavirus vaccines are typically recommended for concomitant 
administration and oral polio vaccine has been found to interfere with rotavirus vaccine in 
the gut and immunogenicity of rotavirus vaccine [45–47].
Researchers are exploring several additional hypotheses that might explain differential 
vaccine performance. Matched case-control studies that included Ghanaian, Pakistani, and 
Dutch infants suggested compelling correlations between gut microbiota composition and 
rotavirus seroconversion following vaccination. However, the sample sizes in these initial 
studies were quite small and a corresponding intervention would need to be proposed and 
tested [48, 49].
There had been some initial concern that immunity induced by RotaTeq and Rotarix 
vaccines may not protect against non-vaccine strains, which was particularly relevant in 
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Africa and Asia, since the distribution of rotavirus strains varied compared to countries 
where rotavirus vaccines were initially developed, tested and introduced [14]. However, a 
meta-analysis of studies from Australia, Belgium, Brazil, Bolivia, El Salvador, Mexico, 
Nicaragua, and the United States showed that RotaTeq and Rotarix provide protection 
against homotypic and heterotypic rotavirus strains [50]. Rotavirus recognizes human histo-
blood group antigens (HBGA) and individuals with Lewis-negative secretor-positive HBGA 
phenotypes have an increased susceptibility to P[8] rotavirus strains, compared to non-
secretors [51, 52]. As this phenotype is more common in African populations than US or 
European populations, researchers have hypothesized that Lewis-negative secretor-positive 
children may be unable to develop protection using the current rotavirus vaccines, as a 
reason for poorer performance of Rotarix and RotaTeq in sub-Saharan Africa. However, 
ROTAVAC uses a G9P[11] strain and its efficacy in India was comparable to Rotarix and 
RotaTeq in medium and high child mortality settings, indicating HBGA status is not the only 
reason for the effectiveness gradient. Further research is needed to determine what role 
HBGAs may play in vaccine-induced immunity against rotavirus and how this might guide 
future vaccine development.
Several programmatic strategies have also been evaluated to boost rotavirus VE, including 
improving nutrition status, recommending alternative ages of administration, timing of 
breastfeeding, and supplementation with zinc [53–63]. Findings from studies that considered 
alternate ages of administration have been mixed, with one study demonstrating improved 
immunogenicity with older administration of Rotarix and two others showing no impact [29, 
56, 64, 65]. There was concern that lower VE may be because rotavirus vaccine is 
neutralized by high maternal antibody in breastmilk in settings with high rotavirus burden. 
However, studies evaluating withholding breastfeeding at the time of vaccination and 
rotavirus vaccine response have not found any relationship [57, 58, 60, 62]. A recent 
randomized control trial in India found a modest improvement in immunogenicity following 
rotavirus vaccination with zinc and probiotic supplementation together; no effect was found 
when rotavirus vaccine was administered with zinc or the probiotic alone, however the 
authors report the dosage of zinc may have been too low [63].
While clinical trials in low child mortality countries did not identify a difference in vaccine 
efficacy between children <12 months of age and children ≥12 months of age, there was 
some evidence suggesting waning vaccine efficacy after first year of life in medium and high 
child mortality countries [65–67]. Similar to the clinical trial findings, in low child mortality 
countries differences between age groups were not found by the systematic review of post-
licensure VE studies with either vaccine. However, Rotarix VE was almost a third higher 
among children <12 month of age in medium child mortality countries compared to children 
≥12 months of age; there was no difference in the summary differences in high child 
mortality countries. RotaTeq VE was nearly 25% higher among children <12 month of age 
in high child mortality countries compared to children ≥12 months of age [38]. The age-
group specific sample sizes in these evaluations were generally too small to detect a 
difference; never the less, the potential waning has important implications for vaccination 
programs. A clinical trial in Bangladesh demonstrated a booster dose at 9 months of age 
improved IgG antibodies against rotavirus; a similarly designed analysis from a clinical trial 
in Mali is forthcoming [68, 69]. These findings have led to optimism that modifying 
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recommendations to include a booster dose of rotavirus vaccine may address the observed 
waning immunity with the currently available vaccines. However further research is needed 
as the published analysis did not include a clinical endpoint to assess vaccine efficacy 
following a rotavirus booster dose [68].
7. Vaccine impact
Despite differential VE, rotavirus vaccines have had a sizeable impact on diarrhea morbidity 
and mortality in low, medium, and high child mortality countries. Following rotavirus 
vaccine introduction, rotavirus mortality decreased by 22% in Brazil and 41% in Mexico 
among children <1 years old [70, 71]. Countries have experienced a reduction in rotavirus 
diarrhea hospitalizations by a median of 67% after including rotavirus vaccine in their 
national immunization programs [72]. In absolute numbers, this translates to thousands of 
hospitalizations prevented each year. For instance, in the first 7 years of rotavirus vaccine 
implementation in the United States, vaccination prevented an estimated 382,000 
hospitalizations and saved over USD$1 billion in direct medical costs [73]. In the 29 African 
countries that had introduced rotavirus vaccine by the end of 2014, nearly 135,000 rotavirus 
hospitalizations and 21,000 rotavirus deaths were estimated to have been prevented in 2016 
[74].
Universal adoption of routine rotavirus vaccination would also reduce the global burden of 
rotavirus disease. As an example, in all African countries that had not introduced rotavirus 
vaccine, including Nigeria and the Democratic Republic of Congo, an additional 119,000 
hospitalizations and 22,000 deaths were projected to be prevented with national, routine use 
of rotavirus vaccines at coverage levels comparable to diphtheria-tetanus-pertussis (DTP) 
vaccines.
8. Safety
An earlier rotavirus vaccine, RotaShield (Wyeth), a rhesus quadravalent rotavirus vaccine 
licensed in the US in 1998, was removed from the market in 1999 after post-licensure safety 
assessments identified a 10-fold (aOR: 10.6, 95%CI:5.7–19.6) elevated risk of 
intussusception, a rare bowel obstruction caused by telescoping of the small intestine, 
following rotavirus vaccination, or approximately 1 excess intussusception case per 10,000 
children vaccinated [75–78].
Large clinical trials of RotaTeq and Rotarix did not detect an increased incidence of 
intussusception following vaccination [17, 18, 79]. Since the licensure of Rotarix and 
RotaTeq in 2006, a slightly increased risk of intussusception has been observed in post-
licensure safety monitoring, especially in the first seven days post-vaccination [80–85]. A 
2015 meta-analysis of intussusception risk following real-world rotavirus vaccination in 
Australia, Brazil, England Mexico, Singapore, and the United States found an elevated risk 
of intussusception in the first 21 days following the first dose of Rotarix (OR: 2.4, 95%CI: 
1.5, 3.8) and the second dose (OR: 1.8, 95%CI: 1.3, 2.4), or roughly 1.9 and 1.5 excess cases 
of intussusception per 100,000 children vaccinated, respectively [86]. In an analysis of the 
risk of intussusception following RotaTeq vaccination in Australia and the US, also found a 
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similar level of risk for the first and second doses [87]. No association between 
intussusception and rotavirus vaccination was found in a retrospective evaluation in South 
Korea, although the number of children included in the analysis was smaller than other post-
licensure studies [88]. As more countries with medium and high child mortality introduce 
rotavirus vaccine, it will be important to evaluate the risk of intussusception specifically in 
those settings.
Over the decade since licensure of Rotarix and RotaTeq, the benefits of rotavirus vaccination 
in decreased hospitalizations and deaths have far outweighed the risks. Initially, WHO 
recommended upper age limits for vaccination to minimize excess cases of intussusception; 
evidence from RotaShield suggested the highest incidence of intussusception was among 
older infants, when the natural incidence of intussusception also increases [75–77]. These 
recommendations were changed in 2009 after models demonstrated 44 rotavirus diarrhea 
deaths would be prevented for every one potential intussusception death if children were 
eligible to receive rotavirus vaccination up to 1 year of age [75, 89]. WHO recommends 
administering rotavirus vaccine to children up to 24 months of age concomitantly with DTP 
vaccine [75].
Newer rotavirus vaccines have evaluated safety in their clinical trials, however the sample 
size was insufficient to detect a small increase in risk, like that observed with Rotarix and 
RotaTeq. The Phase III clinical trials for both ROTAVAC and Rotasiil reported 0 cases of 
intussusception in the first month following any dose of vaccine or placebo [22, 23, 32]. 
Post-licensure safety monitoring will also continue to be important as new vaccines are 
adopted more widely.
9. Vaccines in development
Although the existing rotavirus vaccines have dramatically reduced rotavirus diarrhea 
worldwide, the licensure of additional rotavirus vaccines may address some of the 
limitations of the current vaccines as well as reinforce the market. Several additional live 
oral vaccines are being developed. Lanzhou Institute has completed a Phase III trial for a 
trivalent lamb reassortant rotavirus vaccine (Table 3) [24, 90]. Butantan Instutite completed 
Phase I clinical trials for a pentavalent human-bovine vaccine [91]. A hexavalent bovine-
human rotavirus vaccine by Wuhan Institute of Biological Products (China) is in the process 
of completing Phase I trials [24]. Additionally, Bharat Biotech is developing a liquid stable 
formulation of ROTAVAC.
Two alternative types of rotavirus vaccines are in development that may eliminate the VE 
differential between child mortality settings and the small risk of vaccine-associated 
intussusception. Murdoch Children’s Research Institute (Australia) and PT Biofarma 
(Indonesia) are developing a live oral human rotavirus vaccine from a G3P[6] strain found to 
cause asymptomatic infections in neonates [24]. This strain was selected because it is able to 
replicate in the newborn gut, even in the presence of maternal antibodies, and the strain may 
also offer protection to individuals with a Lewis-negative and secretor-positive phenotype. A 
Phase IIa clinical trial demonstrated this vaccine was immunogenic with both infant (6 
week, 10 week, 14 week) and newborn (birth, 6 week, 10 week) administration schedules 
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[92]. Administration of a rotavirus vaccine to newborns offers other benefits. A birth dose 
could offer protection from diarrheal disease and deaths before any children are exposed to 
wild rotavirus, potentially preventing additional infections that occur between birth and the 
current recommended age administration of the first dose, usually 6 weeks or 2 months of 
age [2, 93]. Other vaccines that have a recommended birth dose, such as polio, Hepatitis B, 
and bacilli Calmette-Guerin (BCG) vaccines, have high vaccination coverage of children <1 
year old; birth dose administration of rotavirus vaccine could improve coverage compared to 
the current infant schedule. Additionally, natural intussusception is rare before three months 
of age [94]; a birth dose may eliminate the vaccine-associated risk of intussusception. This 
vaccine is undergoing in Phase IIb clinical trial [24]. RotaShield has also been considered 
for a neonatal administration schedule; a clinical trial showed 61% efficacy in Ghanaian 
infants vaccinated during the first and second months of life [95].
Non-replicating vaccines with a parenteral delivery strategy have been proposed as a way to 
eliminate the risk of intussusception, since immune response would not be dependent on 
vaccine viruses replicating in the gut. Additionally, these vaccines may not be susceptible to 
the hypothesized reasons for lower VE in medium and high child mortality settings such as 
co-infections, microbiota composition, or interference by oral polio vaccine [24, 96]. 
Intramuscular administration has additionally benefits; for example, it could be included in a 
combination vaccine with other routine infant vaccinations like DTP and pneumococcal 
vaccines (PCV). A subunit vaccine developed by PATH showed safety and immunogenicity 
in a recently completed a Phase I/II descending dose study; an additional Phase I/II study is 
currently underway [97]. To date, none of the clinical trials of these vaccines have included a 
clinical endpoint. Intradermal administration of a whole, inactivated particle vaccine, using a 
microneedle patch of an inactivated vaccine, is also being developed by CDC. Microneedle 
patches have several programmatic advantages, including thermal stability, reduced 
packaging, elimination of sharp biohazardous waste, and ease of administration [98, 99]. 
Additionally, immune response to intradermal administration may allow for a fractional dose 
to be administered, which could improve the supply chain and reduce costs [24, 100].
10. Conclusions
Over the last 11 years, rotavirus vaccines have been safely and effectively implemented in 
more than 80 countries worldwide. Large reductions in rotavirus diarrhea deaths and 
hospitalizations during these period have been sweeping; however, the live, oral rotavirus 
vaccines have been shown to be less effective in medium and high child mortality settings 
than countries with low child mortality. New vaccines in development are promising to 
further reduce the burden of rotavirus diarrhea morbidity and mortality among children <5 
years old.
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Since 2006, two live, oral rotavirus vaccines have reduced the substantial burden 
of rotavirus disease in countries that have introduced the vaccines into their 
national, routine immunization program.
The effectiveness of rotavirus vaccines is lower in high child mortality settings, 
compared to low child mortality settings; while there are several hypotheses, 
including differences in co-infections with other enteropathogens at the time of 
vaccination, gut microbiota composition, and prevalence of Lewis-negative 
secretor-positive histo-blood group antigens, the exact causes for lower vaccine 
performance are unknown.
Other rotavirus vaccines are currently under development that make use of 
alternate rotavirus strains and delivery strategies to ameliorate specific 
programmatic challenges with the currently available vaccines.
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Estimated rotavirus mortality rates by country, 2013.
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Rotavirus vaccine introduction status by country, 2017
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